Literature DB >> 10052650

Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan.

X Liu1, E Sentex, L Golfman, S Takeda, M Osada, N S Dhalla.   

Abstract

In view of the activation of renin-angiotensin system under conditions associated with pressure overload on the heart, we examined the effects of captopril, an angiotensin converting enzyme inhibitor, and losartan, an angiotensin II receptor antagonist, on cardiac function, myofibrillar ATPase and sarcoplasmic reticular (SR) Ca2+-pump (SERCA2) activities, as well as myosin and SERCA2 gene expression in hypertrophied hearts. Cardiac hypertrophy was induced in rats treated with or without captopril or losartan by banding the abdominal aorta for 8 weeks; sham operated animals served as control. Decrease in left ventricular developed pressure, +dP/dt and -dP/dt as well as increase in left ventricular end diastolic pressure and increased muscle mass due to pressure overload were prevented by captopril or losartan. Treatment of animals with captopril or losartan also attenuated the pressure overload-induced depression in myofibrillar Ca2+-stimulated ATPase, myosin ATPase, SR Ca2+-uptake and SR Ca2+-release activities. An increase in beta-myosin heavy chain mRNA and a decrease in alpha-myosin heavy chain mRNA as well as depressed SERCA2 protein and SERCA2 mRNA levels were prevented by captopril or losartan. These results suggest that both captopril and losartan improve myocardial function in cardiac hypertrophy by preventing changes in gene expression and subsequent subcellular remodeling due to pressure overload.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052650     DOI: 10.3109/10641969909068657

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  5 in total

Review 1.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.

Authors:  Y Hayashi; H Ishida; M Hoshiai; K Hoshiai; T Kirimoto; T Kanno; M Nakano; K Tajima; H Miyake; N Matsuura; H Nakazawa
Journal:  Mol Cell Biochem       Date:  2000-06       Impact factor: 3.396

3.  Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil.

Authors:  S Takeo; A B Elmoselhi; R Goel; E Sentex; J Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-10       Impact factor: 3.396

4.  Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.

Authors:  Jarmila Machackova; Xueliang Liu; Anton Lukas; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-06       Impact factor: 3.396

5.  Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach.

Authors:  Oriol Iborra-Egea; Carolina Gálvez-Montón; Santiago Roura; Isaac Perea-Gil; Cristina Prat-Vidal; Carolina Soler-Botija; Antoni Bayes-Genis
Journal:  NPJ Syst Biol Appl       Date:  2017-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.